A Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Safety and Efficacy Of Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced Or Recurrent Non-sm

Status
Approved-not yet active
Cancer Type
Lung Cancer
Trial Phase
Phase II
Eligibility
18 and over, Male and Female
Study Type
Treatment
NCD ID
NCT01493843
Protocol IDs
GO27912 (primary)
Study Sponsor
Genentech Incorporated

Summary

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled trial with four arms that will be conducted at approximately 75 to 100 sites in countries of the European Union (EU), the United States (US), and other select countries.

Treatment Sites in Georgia


University Cancer and Blood Center, LLC - Athens Medical Oncology
3320 Old Jefferson Road
Building 700
Athens, GA 30607
706-353-2990 x279
www.universitycancer.com